Robert Weinberg, Ph.D.

Dr. Weinberg is a founding member of the Whitehead Institute for Biomedical Research and the Daniel K. Ludwig Professor for Cancer Research in the Department of Biology at MIT. Dr. Weinberg is also a founder of Verastem Oncology. Dr. Weinberg is the internationally recognized authority on the genetic basis of human cancer development. Dr. Weinberg is the author or editor of five books and more than 350 articles. Three of the books are intended for a lay audience; “One Renegade Cell,” “Racing to the Beginning of the Road: The Search for the Origin of Cancer” and “Genes and the Biology of Cancer” the latter co-authored with Dr. Harold E. Varmus, former Director of the National Institutes of Health. More recently, Dr. Weinberg has published a textbook “The Biology of Cancer,” which is intended for doctoral students learning about this disease. Dr. Weinberg is a member of the National Academy of Sciences, the Institute of Medicine and a Fellow of the American Academy of Arts and Sciences.

Back to top

Mario Sznol, M.D.

Dr. Mario Sznol is Professor of Internal Medicine, Leader of the Melanoma-Renal Cancer Disease-Associated Translational Research Team, and Co-Leader of the Cancer Immunology Program. Dr. Sznol is also the immediate Past President of the Society for Immunotherapy of Cancer (SITC). He has an international reputation in cancer drug development. Dr. Sznol graduated from Rice University and Baylor College of Medicine (BCM) in Houston, Texas. He trained in internal medicine at BCM and completed a medical oncology fellowship in the Department of Neoplastic Diseases, Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program of the National Cancer Institute, and was Head of the BES from 1994-1999. He attended on the inpatient units of the Biological Response Modifiers Program, NCI, from 1988-1996 and the Immunotherapy Service of the Surgery Branch, NCI, from 1997-1999. From 1999-2004, he served as Vice President of Clinical Development and Executive Officer of Vion Pharmaceuticals in New Haven, Connecticut.

Back to top

Edmund K. Waller, MD

Edmund K. Waller, MD, PhD, FACP

Edmund K. Waller, MD, PhD, FACP is a tenured Professor of Hematology and Medical Oncology, Medicine, and Pathology at Emory University. He is also the Director of the Bone Marrow and Stem Cell Transplant Program at Emory.  Under Dr. Waller’s leadership, the annual number of stem cell transplants performed at Emory has risen from 93 in 2000 to 450 in 2018.  Dr. Waller’s research is funded by the National Cancer Institute, National Heart Lung and Blood Institute as well as the National Marrow Donor Program and the American Society of Hematology.  His research focuses on optimizing antitumor immunity in cancer patients. He has developed novel strategies of regulating immune responses by studying the interaction between T cells and dendritic cells in murine models and using clinical samples from patients. Dr. Waller is the author of over 280 peer-reviewed articles with an h-index of 51. He has trained 30 post-doctoral fellows and directly supervised 8 graduate students. Projects in his laboratory include graft engineering to select donor dendritic cell subsets that enhance graft versus leukemia activities and post-transplant immune reconstitution, novel drugs that target coinhibitory immune pathways and regulate graft-versus-host disease, and development of more effective ways to generate and expand cancer-specific T cells for adoptive therapy. The clinical translational focus of his research is in immunotherapy to treat patients with hematological and solid tumor malignancies, including patients undergoing autologous and allogeneic stem cell transplantation. Prior to Emory, Dr. Waller completed his undergraduate degree at Harvard University, his MD-PhD degree at Cornell-Rockefeller, and his clinical training in Oncology at Stanford University.

Back to top